drugset / Trial / NCT03802565

Tolperisone in Acute Muscle Spasm of the Back

NCT03802565

Phase 2 Completed 415 enrolled Neurana Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a double-blind, randomized, placebo-controlled, parallel group study of the efficacy and safety of tolperisone (a non-opioid) or placebo administered as multiple doses three times a day (TID) in approximately 400 male and female subjects experiencing back pain due to or associated with muscle spasm.

Timeline

Start
2019-02-01
Primary completion
2019-06-28
Completion
2019-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolperisone Small molecule 50 mg
Subject Tolperisone Small molecule 100 mg
Subject Tolperisone Small molecule 150 mg
Subject Tolperisone Small molecule 200 mg

Indications

No indication recorded.